Status and phase
Conditions
Treatments
About
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other inclusion/exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Central Operations Representative
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal